Allarity Therapeutics Files 8-K
Ticker: ALLR · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1860657
Sentiment: neutral
Topics: 8-K, filing, regulation-fd
TL;DR
Allarity Therapeutics filed an 8-K on June 27, 2024. Details to follow.
AI Summary
On June 27, 2024, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt, but it establishes the filing date and company information.
Why It Matters
This filing indicates that Allarity Therapeutics, Inc. is providing updated information to the SEC, which could include material disclosures relevant to investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a high-risk situation.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- June 27, 2024 (date) — Date of earliest event reported
- 001-41160 (other) — Commission File Number
- 24 School Street, 2nd Floor, Boston, MA 02108 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Allarity Therapeutics, Inc.?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported was on June 27, 2024.
What is the Commission File Number for Allarity Therapeutics, Inc.?
The Commission File Number is 001-41160.
Where are Allarity Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA 02108.
What is the Standard Industrial Classification code for Allarity Therapeutics, Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-06-28 08:45:09
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea0208659-8k_allarity.htm (8-K) — 27KB
- ea020865901ex99-1_allarity.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 26KB
- 0001213900-24-056879.txt ( ) — 251KB
- allr-20240627.xsd (EX-101.SCH) — 3KB
- allr-20240627_lab.xml (EX-101.LAB) — 33KB
- allr-20240627_pre.xml (EX-101.PRE) — 22KB
- ea0208659-8k_allarity_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 27, 2024, Allarity Therapeutics, Inc. (the "Company"), issued a press release announcing that the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company was granted a hearing before a Nasdaq hearings panel. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated June 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer Dated: June 28, 2024 2